Assessment of Safety, Tolerability, Pharmacokinetics, and Pharmacological Effect of Orally Administered CORT125134: An Adaptive, Double‐Blind, Randomized, Placebo‐Controlled Phase 1 Clinical Study

CORT125134 is an orally active, high‐affinity, selective antagonist of the glucocorticoid receptor that is being developed for indications that may benefit from the modulation of cortisol activity. This first‐in‐human study was conducted to evaluate the dose‐related safety, tolerability, pharmacokin...

Descripción completa

Detalles Bibliográficos
Autores principales: Hunt, Hazel, Donaldson, Kirsteen, Strem, Mark, Zann, Vanessa, Leung, Pui, Sweet, Suzanne, Connor, Alyson, Combs, Dan, Belanoff, Joseph
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5947602/
https://www.ncbi.nlm.nih.gov/pubmed/28967708
http://dx.doi.org/10.1002/cpdd.389

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5947602/
https://www.ncbi.nlm.nih.gov/pubmed/28967708
http://dx.doi.org/10.1002/cpdd.389

Ejemplares similares